Ironwood Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 267
- Market Cap
- $782.7M
- Introduction
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
- Conditions
- Interstitial CystitisBladder Pain Syndrome
- Interventions
- Drug: PlaceboDrug: IW-3300 rectal foam
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05740007
- Locations
- 🇺🇸
Urology Associates of Mobile, Mobile, Alabama, United States
🇺🇸Velocity Clinical Research, Mobile, Alabama, United States
🇺🇸Ironwood Research Center, Charleston, South Carolina, United States
A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05362695
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05188261
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- Drug: MD-7246Drug: Placebo
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 515
- Registration Number
- NCT03931785
- Locations
- 🇺🇸
Clinical Research Associates, Huntsville, Alabama, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸Arkansas Gastroenterology, North Little Rock, Arkansas, United States
Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03856970
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 614
- Registration Number
- NCT03573908
- Locations
- 🇺🇸
Clinical Research Associates, Huntsville, Alabama, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT03561090
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Alabama Medical Group, PC, Mobile, Alabama, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 609
- Registration Number
- NCT03561883
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Digestive Health Specialists of The Southeast, Dothan, Alabama, United States
🇺🇸Holland Center for Family Health, Peoria, Arizona, United States
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- Conditions
- Chronic Kidney Disease (CKD)Gout
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03226899
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, Arizona, United States
🇺🇸Medvin Clinical Research, Covina, California, United States
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02837783
- Locations
- 🇬🇧
Peter Whorwell, Wythenshawe, Manchester, United Kingdom